Literature DB >> 7933831

Characterization of the Han:SPRD rat model for hereditary polycystic kidney disease.

K Schäfer1, N Gretz, M Bader, I Oberbäumer, K U Eckardt, W Kriz, S Bachmann.   

Abstract

The Han:SPRD rat model for inherited polycystic kidney disease (PKD) was characterized (clinical parameters, morphology, immunohistochemistry and in situ hybridization). Homozygous animals died of uremia after three to four weeks with severe cystic transformation of virtually all nephrons and collecting ducts (serum urea: 616 +/- 195 mg/dl; kidney-to-body weight ratio: > 20%). In heterozygotes, slow progression of the disease led to death between the 12th and 21st month (median: 17 months; serum urea levels above 200 mg/dl). Kidney enlargement was moderate, and cysts were restricted to the cortex and outer medulla. Immunohistochemical markers showed that approximately 75% of the cysts were derived from the proximal tubule. Cystic transformation started in the proximal tubule with a sharp onset of basement membrane alteration and a loss of epithelial differentiation restricted to small focal areas. In these areas, alpha 1(IV) collagen and laminin B1 mRNA were enhanced as revealed by isotopic and non-isotopic in situ hybridization. Fibroblasts underlying the affected tubular portions were involved in matrix overexpression resulting in subepithelial accumulation of immunoreactive collagen IV and laminin. In later stages of cystic transformation distal nephron segments were affected as well. A reversal in epithelial polarity as judged from Na,K-ATPase-immunoreactivity was not observed. Renal immunoreactive renin-status was significantly decreased. Hematocrit was lowered in heterozygotes (40.4 +/- 5.8 vol% compared to 46.7 +/- 1.99 vol% in controls; P < 0.05) and total renal EPO mRNA was reduced to 36 +/- 14% of the mean value of control animals, whereas serum EPO levels were not significantly altered. We conclude that the Han:SPRD rat is a useful model for the study of human ADPKD since both diseases are similar in several aspects. The model is particularly suitable for the study of epithelial-mesenchymal interactions at the beginning of tubular cystic transformation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7933831     DOI: 10.1038/ki.1994.253

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  25 in total

Review 1.  Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney disease.

Authors:  Gustavo Blanco; Darren P Wallace
Journal:  Am J Physiol Renal Physiol       Date:  2013-06-12

2.  The SAM domain of ANKS6 has different interacting partners and mutations can induce different cystic phenotypes.

Authors:  Zeineb Bakey; Marie-Thérèse Bihoreau; Rémi Piedagnel; Laure Delestré; Catherine Arnould; Alexandre d'Hotman de Villiers; Olivier Devuyst; Sigrid Hoffmann; Pierre Ronco; Dominique Gauguier; Brigitte Lelongt
Journal:  Kidney Int       Date:  2015-06-03       Impact factor: 10.612

3.  A new in vitro bioassay for cyst formation by renal cells from an autosomal dominant rat model of polycystic kidney disease.

Authors:  R Pey; J Bach; G Schieren; N Gretz; M Hafner
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999 Nov-Dec       Impact factor: 2.416

4.  Differential rescue of the renal and hepatic disease in an autosomal recessive polycystic kidney disease mouse mutant. A new model to study the liver lesion.

Authors:  B K Yoder; W G Richards; C Sommardahl; W E Sweeney; E J Michaud; J E Wilkinson; E D Avner; R P Woychik
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

Review 5.  Polycystic kidney disease: huge kidneys, huge problems, huge progress.

Authors:  J J Grantham
Journal:  Trans Am Clin Climatol Assoc       Date:  1997

6.  Use of a body condition score technique to assess health status in a rat model of polycystic kidney disease.

Authors:  Debra L Hickman; Melissa Swan
Journal:  J Am Assoc Lab Anim Sci       Date:  2010-03       Impact factor: 1.232

7.  Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease.

Authors:  Yunxia Tao; Jun Kim; Sarah Faubel; Joe C Wu; Sandor A Falk; Robert W Schrier; Charles L Edelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-29       Impact factor: 11.205

8.  Inhibition of Comt with tolcapone slows progression of polycystic kidney disease in the more severely affected PKD/Mhm (cy/+) substrain of the Hannover Sprague-Dawley rat.

Authors:  Susanne N E Boehn; Sonja Spahn; Sabine Neudecker; Andrea Keppler; Marie-Thérèse Bihoreau; Bettina Kränzlin; Priyanka Pandey; Sigrid C Hoffmann; Li Li; Vicente E Torres; Hermann-Josef Gröne; Norbert Gretz
Journal:  Nephrol Dial Transplant       Date:  2013-03-29       Impact factor: 5.992

9.  The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis.

Authors:  Bjoern Buchholz; Bernd Klanke; Gunnar Schley; Gideon Bollag; James Tsai; Sven Kroening; Daisuke Yoshihara; Darren P Wallace; Bettina Kraenzlin; Norbert Gretz; Peter Hirth; Kai-Uwe Eckardt; Wanja M Bernhardt
Journal:  Nephrol Dial Transplant       Date:  2011-07-29       Impact factor: 5.992

10.  Immunolocalization of ion transport proteins in human autosomal dominant polycystic kidney epithelial cells.

Authors:  S R Brill; K E Ross; C J Davidow; M Ye; J J Grantham; M J Caplan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.